Cargando…

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer

BACKGROUND: The impact of non-small cell lung cancer (NSCLC) metabolism on the immune microenvironment is not well understood within platinum resistance. We have identified crucial metabolic differences between cisplatin-resistant (CR) and cisplatin-sensitive (CS) NSCLC cells with elevated indoleami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chunjing, Spector, Sydney A., Theodoropoulos, George, Nguyen, Dan J. M., Kim, Emily Y., Garcia, Ashley, Savaraj, Niramol, Lim, Diane C., Paul, Ankita, Feun, Lynn G., Bickerdike, Michael, Wangpaichitr, Medhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207715/ https://www.ncbi.nlm.nih.gov/pubmed/37226257 http://dx.doi.org/10.1186/s40170-023-00307-1

Ejemplares similares

Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
por: Wangpaichitr, Medhi, et al.
Publicado: (2021)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

N′(1),N′(3)-Dimethyl-N′(1),N′(3)-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS)
por: Wangpaichitr, Medhi, et al.
Publicado: (2009)

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
por: Wu, Chunjing, et al.
Publicado: (2021)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor
por: Wangpaichitr, Medhi, et al.
Publicado: (2002)

Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
por: Li, Ying-Ying, et al.
Publicado: (2017)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer
por: Wangpaichitr, Medhi, et al.
Publicado: (2017)

Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
por: Li, Ying‐Ying, et al.
Publicado: (2017)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know
por: Bhatia, Shivank, et al.
Publicado: (2016)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Identification and optimisation of next generation inhibitors of IDO1 and TDO
por: Wise, Alan, et al.
Publicado: (2015)

Role of IDO and TDO in Cancers and Related Diseases and the Therapeutic Implications
por: Ye, Zixiang, et al.
Publicado: (2019)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy
por: Kuo, Macus Tien, et al.
Publicado: (2021)

Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation
por: Long, Yan, et al.
Publicado: (2016)

Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
por: Kim, Minah, et al.
Publicado: (2021)

Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer
por: Wangpaichitr, M, et al.
Publicado: (2017)

Induction of TDO2 and IDO2 in Liver by High-Fat Feeding in Mice: Discrepancies with Human Obesity
por: Poulain-Godefroy, Odile, et al.
Publicado: (2013)

Preclinical PK investigation of a novel IDO1/TDO dual inhibitor—SHR9146 in mouse plasma and tissues by LC-MS/MS
por: Xiao, Mei, et al.
Publicado: (2023)

Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
por: Sari, Suat, et al.
Publicado: (2019)

Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
por: Zhang, Rongjie, et al.
Publicado: (2022)

Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020)

IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era
por: Chen, Xiangli, et al.
Publicado: (2020)

Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
por: Kuo, Macus Tien, et al.
Publicado: (2019)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression
por: Tsai, Wen-Bin, et al.
Publicado: (2017)

TDO Promotes Hepatocellular Carcinoma Progression
por: Li, Shanbao, et al.
Publicado: (2020)

Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2
por: Tijono, Sofian M, et al.
Publicado: (2022)

Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021)

Comprehensive Analysis of the Expressionand Prognosis for TDO2 in Breast Cancer
por: Liu, Qiang, et al.
Publicado: (2020)

Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
por: Pham, Quoc Thang, et al.
Publicado: (2021)

Wideband TDoA Positioning Exploiting RSS-Based Clustering
por: Fuchs, Andreas, et al.
Publicado: (2023)

Extracellular Vesicles Secreted by TDO2-Augmented Fibroblasts Regulate Pro-inflammatory Response in Macrophages
por: Peck, Kiel A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_31crg3i9jmf5e8c4eli0mtsnn4